Elliot M. Epner - Publications

Affiliations: 
University of Arizona, Tucson, AZ 
Area:
Oncology, Molecular Biology, Genetics, Cell Biology

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 LeBlanc FR, Hasanali ZS, Stuart A, Shimko S, Sharma K, Leshchenko VV, Parekh S, Fu H, Zhang Y, Martin MM, Kester M, Fox T, Liao J, Loughran TP, Evans J, ... ... Epner EM, et al. Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma. Oncotarget. 13: 986-1002. PMID 36093297 DOI: 10.18632/oncotarget.28258  0.346
2019 Spurgeon SE, Sharma K, Claxton DF, Ehmann C, Pu J, Shimko S, Stewart A, Subbiah N, Palmbach G, LeBlanc F, Latour E, Chen Y, Mori M, Hasanali Z, Epner EM. Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. British Journal of Haematology. PMID 31177537 DOI: 10.1111/bjh.16008  0.347
2008 Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, et al. Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders Biology of Blood and Marrow Transplantation. 14: 246-255. PMID 18215785 DOI: 10.1016/J.Bbmt.2007.11.012  0.532
2007 Kahl C, Storer BE, Sandmaier BM, Mielcarek M, Maris MB, Blume KG, Niederwieser D, Chauncey TR, Forman SJ, Agura E, Leis JF, Bruno B, Langston A, Pulsipher MA, McSweeney PA, ... ... Epner E, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 110: 2744-8. PMID 17595333 DOI: 10.1182/blood-2007-03-078592  0.455
2006 Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL, Goy A. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4867-74. PMID 17001068 DOI: 10.1200/JCO.2006.07.9665  0.314
2006 Franke GN, Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Stuart M, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Poenisch W, Grommisch L, Al-Ali H, ... ... Epner E, et al. Treatment for acute myelogenous leukemia by low dose Total Body Irradiation (TBI) based conditioning and hematopoietic cell transplantation from related and unrelated donors Biology of Blood and Marrow Transplantation. 12: 31-32. DOI: 10.1016/J.Bbmt.2005.11.096  0.433
2005 Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia. 19: 990-7. PMID 15800667 DOI: 10.1038/Sj.Leu.2403730  0.525
2004 Kerbauy FR, Lange T, Gooley T, Shizuru J, Radich J, Maloney DG, Agura E, Bruno B, Epner E, Chauncey T, Blume K, Storb R, Niederwieser D, Sandmaier BM. Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML. Blood. 104: 2316-2316. DOI: 10.1182/Blood.V104.11.2316.2316  0.533
2003 Hegenbart U, Niederwieser D, Forman S, Holler E, Leiblein S, Johnston L, Pönisch W, Epner E, Witherspoon R, Blume K, Storb R. Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria Biology of Blood and Marrow Transplantation. 9: 689-697. PMID 14652852 DOI: 10.1016/S1083-8791(03)00264-7  0.53
Show low-probability matches.